[CAS NO. 441785-24-6] LB80317
PRODUCTS SPECIFICATIONS [441785-24-6]
DESCRIPTION [441785-24-6]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 315.22 |
| Molecular Formula | C10H14N5O5P |
| SMILES | OP(O)(COC1(CN2C=NC3=C2N=C(N)NC3=O)CC1)=O |
Summary
IC50 & Target
EC50: 0.5 μM (DNA synthesis of HBV) [2]
In Vitro
After phosphorylation to di- and triphosphate forms, LB80317 is incorporated into the viral DNA inside the nucleocapsid, which inhibits further DNA synthesis. In in vitro studies using cell line models, the drug concentrations causing 50% reduction in HBV DNA produced (EC 50 ) is 0.5 μM for LB80317 [2] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Forty percent of the amount of LB80331/LB80317 in the mouse liver is detected as the phosphorylated form. LB80380 is rapidly absorbed and converted to LB80331. LB80317 has a long half-life at steady-state (T 1/2 =8.3-9.9 hours) [1] .
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
References
- [1] Man-Fung Yuen, et al. Pharmacokinetics of LB80331 and LB80317 Following Oral Administration of LB80380, a New Antiviral Agent for Chronic Hepatitis B (CHB), in Healthy Adult Subjects, CHB Patients, and Mice. Antimicrob Agents Chemother. 2009 May;53(5):177
- [2] Lung-Yi Mak, et al. Pharmacokinetic Evaluation of Besifovir for the Treatment of HBV Infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14(1):101-106.